MedTrace Logo

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

NCT03139253 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-05-03

No results posted yet for this study

Summary

Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.

Conditions

  • Antimicrobial Susceptibility Testing
  • Triple Therapy

Interventions

DRUG

amoxicillin

amoxicillin 1000 mg bid. for 14 days

DRUG

clarithromycin

clarithromycin 500 mg bid. for 14 days.

DRUG

tinidazole

tinidazole 500 mg bid. for 14 days.

DRUG

levofloxacin

levofloxacin 500 mg qd. for 14 days.

DRUG

furazolidone

furazolidone 100 mg bid. for 14 days.

DRUG

tetracycline

tetracycline 750 mg bid. for 14 days.

DRUG

Ilaprazole

Ilaprazole 5 mg bid. for 14 days.

Sponsors & Collaborators

  • Yanqing Li

    lead OTHER

Principal Investigators

  • Li Yanqing, MD, PhD · Qilu Hospital of Shandong University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-30
Primary Completion
2017-06-30
Completion
2017-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03139253 on ClinicalTrials.gov